Results 11 to 20 of about 710,185 (341)

Unattended automated office blood pressure measurement — current evidence and the role in clinical practice

Arterial Hypertension, 2021
Arterial hypertension is a leading preventable cardiovascular risk factor. The definition and thresholds for the diagnosis of hypertension vary between European and American guidelines.
Marek Stopa, Agnieszka Olszanecka, Marek Rajzer   +2 more
doaj   +1 more source

Myocardial infarction caused by Graves’ disease

Endokrynologia Polska, 2021
Not required for Clinical Vignette.
Marek Kuch, Magdalena Rostek, Marek Chmielewski, Monika Bargieł   +3 more
doaj   +1 more source

Prevalence and clinical implications of atrial fibrillation in patients hospitalized due to COVID-19: Data from a registry in Poland

Frontiers in Cardiovascular Medicine, 2023
BackgroundAtrial fibrillation (AF) is a common arrhythmia with increasing prevalence with respect to age and comorbidities. AF may influence the prognosis in patients hospitalized with Coronavirus disease 2019 (COVID-19).
Michał Terlecki, Wiktoria Wojciechowska, Marek Klocek, Tomasz Drożdż, Maryla Kocowska-Trytko, Paweł Lis, Christopher Pavlinec, Jan W. Pęksa, Michał Kania, Zbigniew Siudak, Andrzej Januszewicz, Reinhold Kreutz, Maciej Małecki, Tomasz Grodzicki, Marek Rajzer, CraCov HHS Investigators   +15 more
doaj   +1 more source

Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]

, 2015
. Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Ariff, B, Davies, R, Gibbs, JS, Gin-Sing, W, Howard, L, Jaijee, SK, O'Regan, DP   +6 more
core   +1 more source

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension

BMC Pulmonary Medicine, 2017
Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum, Kaaja M. Baaske, Marcel Simon, Tim Oqueka, Christoph Sinning, Antonia Glatzel, Nicole Lüneburg, Karsten Sydow, Carsten Bokemeyer, Hans Klose   +9 more
doaj   +1 more source

Transient but not genetic loss of miR-451 attenuates the development of pulmonary arterial hypertension [PDF]

, 2013
<b>Rationale:</b> MicroRNAs are small non-coding RNAs involved in the regulation of gene expression and have recently been implicated in the development of pulmonary arterial hypertension (PAH).
Baker, Andrew H., Dempsie, Yvonne, Grant, Jennifer S., MacLean, Margaret R., Morecroft, Ian, van Rooij, Eva   +5 more
core   +2 more sources

Resistant hypertension after renal infarction in a man with fibromuscular dysplasia

Blood Pressure, 2021
We report the case of 39-year-old Caucasian man presenting in emergency department with new onset of severe hypertension with hypokalaemia eight weeks after renal colic. Patient was referred to a hypertension unit for further investigation.
Nikolina Bukal, Dražen Perkov, Luka Penezić, Bojan Jelaković, Živka Dika   +4 more
doaj   +1 more source

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension

ERJ Open Research, 2023
Background Converging evidence from proteogenomic analyses prioritises thrombospondin-2 (TSP2) as a potential biomarker for idiopathic or heritable pulmonary arterial hypertension (PAH).
Anna M. Dittrich, Julia Mienert, Julian Pott, Lena Engels, Christoph Sinning, Jan K. Hennigs, Hans Klose, Lars Harbaum   +7 more
doaj   +1 more source

MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]

, 2020
Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang, Chen, Shanshan, Chou, Chih-Hung, Cui, Xiaopei, Fan, Fenling, Gongol, Brendan, Gu, Mingxia, He, Ming, He, Yangyang, Huang, Hsien-Da, Jing, Zhi-Cheng, Lei, Yuyang, Li, Zhao, Malhotra, Atul, Miao, Yifei, Rabinovitch, Marlene, Shen, Yuan, Shyy, John Y-J, Wang, Xiaojian, Yan, Xiaosong, Zhang, Jiao, Zhang, Jin, Zhang, Yixin   +22 more
core   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source